Form 4: Jasper Therapeutics CEO Ron Martell Awarded Stock Options

Ron Martell, CEO and Director of Jasper Therapeutics, was granted stock options for 130,000 shares on February 13, 2025.

Summary

• Ron Martell, the President, CEO, and Director of Jasper Therapeutics, Inc., was granted stock options on February 13, 2025.
• The stock option allows Martell to purchase 130,000 shares of Voting Common Stock at an exercise price of $6.20 per share.
• The options vest over a four-year period, with 1/4th vesting on February 13, 2026, and the remaining 1/48th vesting monthly thereafter, contingent upon continuous service to Jasper Therapeutics.
• The options expire on February 13, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a common practice and generally viewed as a positive sign of aligning management interests with shareholders. The vesting schedule promotes long-term commitment.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The vesting of the stock options is contingent upon the Reporting Person's continuous service to the Issuer.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to increase company value.
• The CEO is incentivized to remain with the company due to the vesting schedule.

Key Dates